Clinical Observation of Magnesium Isoglycyrrhizinate in Treatment of HBV-Related Liver Cirrhosis

目的：观察异甘草酸镁对于乙型肝炎肝硬化患者的临床应用优势。方法：将65例乙型肝炎肝硬化患者，随机分为治疗组(33例)和对照组(32例)，分别给予异甘草酸镁和甘草酸二铵常规治疗，疗程14天，比较治疗前后谷丙转氨酶(ALT)、谷草转氨酶(AST)、Na+、K+、腹围、白蛋白使用量的变化情况。结果：1)组间治疗后比较，治疗组ALT、AST水平降低更显著，差异有统计学意义(P +、K+浓度均无显著性差异(P > 0.05)；3) 组间比较，治疗组腹围降低更显著，差异有统计学意义(P 0.05)。结论：异甘草酸镁对乙型肝炎肝硬化患者，具有较好的保肝作用，可以维持腹围的稳定，改善病人的生活质量。 Objective: To evaluate the therapeutic efficacy of magnesium isoglycyrrhizinate (MIG) in treatment of HBV-related d liver cirrhosis. Methods: Sixty-five HBV-related liver cirrhosis patients were assigned to two groups by using a random number table: MIG treatment group (n = 33), and control group treated with Diammonium Glycyrrhizinate (n = 32). In all cases, the treatment course was 14 days. Alanine transaminase (ALT), aspartate aminotransferase (AST), Na+, K+, abdominal circumference, used amount of albumin were evaluated in both groups before and after treatment. Results: 1) After treatment, the reducing of ALT, AST was significant different between groups (P +, K+ was not significant different between groups (P > 0.05). 3) After treatment, abdominal circumference was significant different between groups (P 0.05). Conclusion: MIG has a good therapeutic effect in treatment of HBV-related liver cirrhosis with improvement of liver function, abdominal circumference and the patient’s life quality.